The use of AAV, the gold-standard viral vector for gene therapy, has successfully progressed from preclinical studies to multiple FDA-approved therapies. This transition has placed further emphasis on developing less expensive and more efficient manufacturing processes, as well as identifying new capsids to more effectively target specific tissues and cell types. This webinar will feature cutting edge developments in the areas of AAV capsid design and scalable manufacturing.
Speakers:
- Cagla Asku Küz
- Susumu Uchiyama
Moderator: Dan Stone, PHD, Fred Hutch Caner Center